Drug hypersensitivity includes allergic (AR) and nonallergic reactions (NARs) influenced by genetic predisposition. We performed a systematic review of genetic predictors of IgE-mediated AR and NAR with MEDLINE and PubMed search engine between January 1966 and December 2014. Among 3110 citations, the search selected 53 studies, 42 of which remained eligible. These eligible studies have evaluated genetic determinants of immediate reactions (IR) to beta-lactams (n = 19), NAR against aspirin (n = 12) and other nonsteroidal anti-inflammatory drugs (NSAIDs) (n = 8), and IR to biologics (n = 3). We reported two genomewide association studies and four case-control studies on candidate genes validated by replication. Genes involved in IR to beta-lactams belonged to HLA type 2 antigen processing, IgE production, atopy, and inflammation, including 4 genes validated by replications, HLA-DRA, ILR4, NOD2, and LGALS3. Genes involved in NAR to aspirin belonged to arachidonic acid pathway, membranespanning 4A gene family, histamine production pathway, and pro-inflammatory cytokines, while those involved in NAR to all NSAIDs belonged to arachidonic acid pathway and HLA antigen processing pathway. ALOX5 was a common predictor of studies on NAR to both aspirin and NSAIDs. Although these first conclusions could be drawn, this review highlights also the lack of reliable data and the need for replicating studies in contrasted populations, taking into account worldwide allele frequencies, gene-gene interactions, and contrasted situations of environmental exposure.
Adverse drug reactions are defined by the World Health Organization as noxious and unintended responses to drugs at normal doses (1) . The classical pharmacological classification of adverse drug reactions by Rawlins and Thompson distinguishes two types: type A reactions, which are dosedependent and predictable, and type B, which are not dosedependent and are unpredictable (2) . Type B reactions include hypersensitivity reactions produced by the release of cellular mediators through both immune and nonimmune mechanisms (3, 4) . Allergy reactions (AR) refer to hypersensitivity reactions for which typically either an IgE or non-IgE mechanism -like T-cell-mediated mechanism -is demonstrated either with positive skin tests or in vitro tests (e.g., specific IgE or cellular tests) while nonallergic reactions (NARs) refer to those for which no specific immunological mechanism can be demonstrated (5) (6) (7) .
According to the International Consensus on drug allergy, hypersensitivity reactions are commonly classified as immediate or nonimmediate, depending on the time interval between the last drug administration and the manifestations of the reaction (8, 9) . Immediate reactions occur within the first hour after the last drug administration and are manifested as urticaria, angioedema, rhinitis, bronchospasm, or anaphylaxis. Nonimmediate reactions may occur at any time from 1 h after the initial drug administration and are often induced by T cells and other mechanisms.
We have performed a systematic review on genetic variants associated with drugs-induced immediate hypersensitivity reactions, using a highly sensitive search strategy, which was applied to retrieve all articles from electronic bibliographic databases.
Materials and methods

Selection criteria and data extraction
The literature search was conducted using MEDLINEindexed literature using the PubMed search engine from the National Center for Biotechnology Information (www.pubmed.gov) (January 1966 to October 2014), using the following medical subject heading (MeSH) terms: [(Receptors, IgE) OR (Immunoglobulin E) OR (E, Immunoglobulin) OR IgE OR (Hypersensitivity, Immediate) OR allergy OR anaphylactic OR anaphylaxis] vs AND (Therapeutics OR Drugs OR (Drug Hypersensitivity) OR (Drug Hypersensitivity Syndrome) OR Penicillins OR betaLactams OR betalactams OR (Anti-Inflammatory Agents, Non-Steroidal) OR aspirin) AND (Genes OR (Polymorphism, Genetic) OR (Polymorphism, Single Nucleotide) OR (High-Throughput Nucleotide Sequencing) OR (GenomeWide Association Study) OR genetic variant OR immunochip) (See supplementary methods for the exhaustive MeSH term-based search strategy). Additional articles were retrieved from primary search references. A study was considered eligible for the systematic review if it has assessed the potential association between at least one genetic variant and a drugsinduced immediate hypersensitivity reaction phenotype. Both candidate gene and genomewide association study approaches were eligible for the systematic review. No language restrictions were applied.
The following data were extracted, when available, based on a predefined protocol using Microsoft Excel Ò : author; year; geographical region; study design (case-control, cohort, family-based); study approach (candidate gene, genomewide association study), number of cases, clinical phenotype of cases, number of controls, clinical phenotype of controls, discovery/initial cohort, validation/replication cohort, genetic variants with their corresponding genes or loci, and effect sizes (odds ratios or hazard ratios); nominal P-values and multiple-correction P-values when applicable; functional validation; and proportion of positive drug-specific IgE among patients with immediate-type hypersensitivity to beta-lactams. Two investigators (AO, J-LG) independently reviewed the titles and abstracts of all citations identified by the literature search. Eligible articles were reviewed in duplicate in an independent manner by the two investigators. Disagreement in data extraction was resolved by consensus. All eligible studies were assessed for their quality using the validated STREGA reporting recommendations framework (STrengthening the REporting of Genetic Association Studies) (10) . A quantitative 'STREGA score' was calculated for each study and was based on a list of 25 items. Concomitantly, selected articles were rated in three categories according the level of evidence as follows: high (A), studies with adequate study power and replication/ validation, for which further research is very unlikely to change our confidence in the risk association of the gene predictor; good (B), studies with adequate study power but no reported replication/validation, for which further research may have an impact on the estimates of the risk association; and moderate (C), studies with inadequate study power and no reported replication, for which further research is very likely to have an impact on the estimates of risk association. Adequate population size was defined with a study power 1-b = 0.9 and a = 0.05, a genotype relative risk at 2.0, and a disease prevalence at 0.01, assuming both allelic and additive models, according to the algorithm of Skol et al. (11) . Table S1 reports the study power calculation according to disease-related allele frequency assuming both allelic and additive genetic models.
Results
Literature search results
The search strategy generated 3110 citations of which 53 appeared to be relevant to the systematic review. Only publications dealing with evaluation of genetic predictors of immediate-type immune and nonimmune reactions to drugs were selected. Of these 53 studies, eleven were excluded for the following reasons: drug association with asthma, in eight cases, letter to the editor without reporting original in two cases and genotype data not clearly reported in one case (see Table S2 for detailed exclusion grounds for articles excluded from the systematic review), leaving 42 studies eligible to the systematic review (Fig. 1 ). Among the 42 selected studies that reported genetic predictors in association with immediate-type hypersensitivity, 19 were related to BLs (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (Table 1), 12 to aspirin (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (Table 2) , and eight to other NSAIDs (43-50) (Table 3) . Three studies reported genetic predictors in association with biologicals, including hypersensitivity to asparaginase (51), EGF receptor inhibitors (52) , and infliximab (53) ( Table 4) . Tables S3 to 6 report quality assessment of the 42 eligible studies according to the STREGA recommendations (10) . The studies on IR to BLs found an association with genes that were previously identified as predictors of atopy, increased IgE production and inflammation, at least in Europe, China, and US. In contrast, the genetic predictors of hypersensitivity reactions to aspirin and other NSAIDs are mainly due to mechanisms related to their influence on the synthesis and release of newly formed mediators.
Genetic predictors of IgE-dependent reactions to beta-lactam antibiotics (BLs)
Among 19 studies evaluating the potential genetic predictors associated with AR to BLs (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , only one study used a GWAS approach (29) . Four studies replicated the discovery study in a distinct population (27) (28) (29) (30) . Two studies showed the involvement of the MS4A2 gene (membrane-spanning four domains, subfamily A, member 2) (13, 26) . MS4A2 encodes the beta subunit of the high-affinity IgE receptor, which is a member of the membrane-spanning 4A gene family. Twelve studies suggested the involvement of pro-inflammatory cytokines (IL4R, IL4, IL13, IL10, TNF, IFNGR1 , and IL18) in the genetic determinism of BL immediate-type hypersensitivity (14-16, 18-25, 27) . One study demonstrated a positive association with NOD2 genetic variants and BL immediate-type hypersensitivity (28) . A genomewide association study using the Immunochip fine-mapping array demonstrated the association between HLA-DRA genetic variants and penicillin allergy in Spanish populations (29) . The study was replicated in an Italian population (29) . The implication of HLA-DRB was suspected on a preliminary Chinese study, which was not validated by replication (17) ( Table 1) . Little attention has been devoted to genes of IgE/FceRI pathway.
LGALS3 was the strongest genetic predictor of BL allergy reported so far, in a recent study performed in two case-control studies from Spain and Italy. The rs11125 predicted BL allergy with odds ratios of 4.0 and 5.1, in Spanish and Italian populations, respectively. It predicted also an increased serum level of total IgE in Spanish controls. Considering all the data together, one group of genes, IL4R, IL4, IL13, IL10, IFNGR1, IL18, and STAT6, showed established functional and/or physical interactions related to IgE production, atopy, and inflammation (Fig. 2) .
Genetic predictors of nonallergic reactions to nonsteroidal anti-inflammatory drugs (NSAIDs)
Twelve studies reported genetic predictors in association with NAR to aspirin only and eight studies reported genetic predictors in association with NARs to NSAIDs, including aspirin. According to the clinical phenotype of the patients, NARs to NSAIDs have been classified in three categories (European Academy of Allergy and Clinical Immunology classification): (i) NSAIDs-exacerbated respiratory disease (NERD), defined as hypersensitivity reactions manifesting primarily as bronchial obstruction, dyspnea, and nasal congestion/rhinorrhea, occurring in patients with an underlying chronic airway respiratory disease (asthma/rhinosinusitis/ nasal polyps). Previously used synonyms for this condition are as follows: aspirin triad, asthma triad, Samter's syndrome, Widal syndrome, aspirin-induced asthma or aspirinsensitive rhinosinusitis/asthma syndrome, aspirin-intolerant asthma, and aspirin-exacerbated respiratory disease; (ii) NSAIDs-exacerbated cutaneous disease (NECD), defined as hypersensitivity reactions manifesting as wheals and/or angioedema occurring in patients with a history of chronic spontaneous urticaria. Previously used synonyms for this condition are as follows: aspirin-induced urticaria and aspirin-exacerbated cutaneous disease; and (iii) NSAIDsinduced urticaria/angioedema (NIUA), defined as hypersensitivity reactions manifesting as wheals and/or angioedema occurring in otherwise healthy subjects (without history of chronic spontaneous urticaria). Symptoms are induced by at least two NSAIDs with different chemical structure (not belonging to the same chemical group) (54) . On the other hand, immunologically mediated (non-cross-reactive) hypersensitivity reactions to NSAIDs encompass two categories (EAACI classification): (i) single-NSAID-induced urticaria/ angioedema or anaphylaxis (SNIUAA), which corresponds to an immediate hypersensitivity reactions to a single NSAID or to several NSAIDs belonging to the same chemical group, manifesting as urticaria, angioedema and/or anaphylaxis; and (ii) single-NSAID-induced delayed hypersensitivity reactions (SNIRD), which is defined by hypersensitivity reactions to a single NSAID appearing usually within 24-48 h after drug administration and manifesting by either skin symptoms (54) .
Genetic predictors of NAR to aspirin
Studies that have assessed the genetic variants potentially associated with immediate-type hypersensitivity to aspirin were predominantly conducted in Korea. They highlighted the involvement of genes that can be grouped into four pathogenic groups: (i) the membrane-spanning 4A gene family (FCER1A (formerly, FceR1a), MS4A2 (formerly, FceR1b), and FCER1G (formerly, FceR1c); (ii) the histamine production pathway (HNMT) (34, 35, 38) ; (iii) the inflammatory cytokines (TGFB1, TNF, and IL18) (36, 37, 40) ; and (iv) the arachidonic acid pathway (ALOX5, LTC4S, TBXA2R, and PTGER4) (33, 39, 41, 42) (Table 2 Fig. 3) . Two groups of genes showed functional and/or physical interactions; two genes involved in the arachidonic acid pathway, ALOX5, LTC4S; and 3 genes involved in the FceRI pathway FCER1A, MS4A2, and FCER1G (Fig. 3) .
Genetic predictors of NAR to NSAIDs, including aspirin
Studies that have assessed the genetic variants potentially associated with immediate-type hypersensitivity to NSAIDs were predominantly conducted in Spain (41) (42) (43) (44) (45) (46) (47) (48) . They reported an association with genes belonging to HLA genes (HLA-DRB1, HLA-B44, and HLA-Cw5) (43, 44) or to the arachidonic acid pathway (ALOX5, ALOX5AP, ALOX15, TBXAS1, PTGDR, and CYSLTR1) (46, 49) ( Table 3) . A case-control study evaluated the histamine-producing pathway and showed a weak association with the diamine oxidase gene (DAO) (43) . Only one study used a GWAS approach and suggested the potential implication of the CEP68 gene (encoding centrosomal protein of 68 KDa) in the development of hypersensitivity reactions to NSAIDs (48) .
Genetic predictors of immediate-type hypersensitivity to other drugs
A GWAS in children with acute lymphoblastic leukemia (ALL) found an association of GRIA1, a gene encoding the glutamate receptor AMPA1 with the risk of allergy to asparaginase (49) . The GRIA1 gene is on chromosome 5q33, a region previously associated with asthma and atopy (55, 56) . Two studies have evaluated the genetic determinants of immediate-type hypersensitivity reactions to biological therapies, namely EGFR inhibitors (52) and infliximab (53) and pointed out HLA genes (HLA-A) and inflammatory cytokines pathway (FASLG, TNFRSF1B), respectively (Table 4) .
Discussion
In the present systematic review regarding genetic variants associated with drugs-induced immediate hypersensitivity reactions, aspirin and other NSAIDs were the most frequently studied drugs in NAR, while BLs were most frequently involved in AR.
Genetic predictors of IgE-mediated AR: the example of betalactams
Genetic predictors at the cross-point between inflammation and allergy Tumor necrosis factor-alpha (TNF-a) is a master pro-inflammatory cytokine, which plays also a role in allergy through its release from mast cells via an IgE-dependent mechanism.
The variant G>A at À308 of TNF is part of an extended haplotype HLA-A1-B8-DR3-DQ2 and influences the gene expression. In central Italy, TNF À308GG genotype was a significant independent predictor of the primary risk for BL allergy, concurrently with total IgE level, in a large case-control study (21) . In addition, cases with TNF À308AA genotype had a higher serum level of specific IgE to penicillin antigens than those with À308GA/GG genotype, suggesting an ambivalent influence of a genetic determinant of proinflammatory pathways on IgE-mediated hypersensitivity to beta-lactams (21) . Polymorphisms of nucleotide-binding oligomerization domain genes NOD2 and NOD1, associated with chronic inflammation and with atopy, are implicated in immunological and inflammatory diseases such as graft-versus-host and Crohn's diseases. They are implicated in the recognition of intracellular bacterial small molecules and modulate inflammatory pathways and T-regulator/T-helper 2 cells' balance (57) . NOD2 and NOD1 polymorphisms are associated with atopy and high total IgE in serum (58, 59) . To evaluate the association of NOD2 and NOD1 polymorphisms with BL allergy, three polymorphisms of NOD2 and one polymorphism of NOD1 were studied in 368 Italian and 387 Spanish patients, compared with 368 and 326 controls, respectively (28) . CT/TT genotypes of rs2066845 of NOD2 predicted a lower risk of immediate-type BL allergy among Italian, while WT/insC genotype of rs5743293 (also in leucine-rich repeat domain of NOD2) predicted a higher risk among Spanish. The G allele of rs2066845 was associated with a higher level of IgE in the Italian population. The mirrored influence of these NOD2 polymorphisms on BL allergy in the two populations suggests a link with inflammation and/or atopy through mechanisms that remain to be clarified (28) .
Genetic predictors of IgE production
The several studies reported in Europe, China, and US converged in showing that AR to BLs are influenced by genes that are involved in IgE production, including those of the IL13 and IL4 pathways (14, 16, 18, 20, 60) . The association between immediate allergic reactions to BLs and polymorphisms of IL13 (R130Q and À1055C>T variants), IL4R (I50V, S478P, and Q551R variants) has been evaluated in patients and their matched control subjects from central Italy and the south of Spain (16) . The combination of the minor allele of the IL13 R130Q polymorphism with any of the predominant homozygous genotypes of the three polymorphisms of IL4R was more significantly associated with the risk of BL allergy than any other polymorphism considered alone (16) . The same associations were observed with serum IgE levels. On the contrary, in Spain, IL13 and IL4R had no epistatic influence and only IL4R I50V and Q551R were predictors of BL AR (27) . These gene variants were also associated with IgE against prevalent allergens and total IgE, respectively. The contrasted influence of IL4R on the risk of BL allergy could be related to differences in allele frequencies and gene-environment interactions (27, 61) . IL4RA predicted not only BL AR but also the concentration of total IgE and the positivity of specific IgE against prevalent allergens, in *Nomenclature according to the European Academy of Allergy and Clinical Immunology (EAACI) classification of hypersensitivity to nonsteroidal anti-inflammatory drugs (54) .
the Spanish population. This suggested that IL4RA was associated with BL allergy through its influence on atopy in South Spain, where the exposure to house dust mite was high (27) . The IL4R R551 allele was associated with penicillin allergy in China (23) . Another study performed in the South of France found a significant association of BL AR with IL4R I50V and IL10 promoter (À819C>T and À592C>A), in female patients with atopy (18) . In consistence with these results, the À1082G allele in IL10 promoter was associated with specific IgE positive antibodies in patients with BL allergy, in China (19) . IL4 and IL13 bindings to receptor subunits activate the signal transducer and activator of transcription (STAT) 6 signaling pathway, which plays an important role in the induction of IgE synthesis. Consistently, an association between STAT6 variants and penicillin allergy has been found in China (25), however, not in Spain (27) .
IL18 activates T cells and increases interferon (IFN)-c, but it can also stimulate the production of Th2 cytokines, suggesting a potential influence in allergy. IL18 À607A/C and À137G/C promoter polymorphisms were associated with susceptibility to penicillin AR, in China (24) .
The high-affinity receptor for IgE (FceR1-b, renamed MS4A2 according to the updated Human Gene Nomenclature Committee nomenclature) plays a central role in the induction and maintenance of IgE sensitization and is associated with elevated total and specific IgE levels. The FceR1b À109T>C polymorphism influences the promoter activity and may be a potential genetic risk factor for increased IgE sensitization to cephalosporins in occupational allergy of health care workers (26) . Another study reported an association of the FceR1b E237G polymorphism with penicillin AR in the Chinese population (13) .
The MHC-encoded susceptibility genes A fine-mapping genomewide association study of the genetic predictors of BL allergy was recently performed in patients with immediate allergic reactions to BLs from Spain and was replicated in patients from Italy (29) . This study found significant associations of HLA-DRA rs7192 and rs8084 with allergy to penicillins and amoxicillin but not to cephalosporins. A haplotype block in HLA-DRA and HLA-DRA | HLA-DRB5 inter-region encompassed a motif involved in balanced expression of a-chain and b-chains of MCH class II, while rs7192 was predicted to influence a-chain conformation (29) . These gene variants of HLA-DRA and HLA-DRA | HLA-DRB5 intergenic region have been also associated with IgE-mediated sensitization to prevalent allergens (29) , suggesting complex gene-environment interactions of BL allergy, in which genetic susceptibility of HLA type 2 antigen presentation could play a central role. An increased frequency of HLA-DR9 has also been reported in the Chinese population, which has not been replicated (29) .
Genetic predictors of NAR: the examples of nonspecific reactions against Aspirin and NSAIDs
The MHC-encoded susceptibility genes Between 1999 and 2014, eight studies, mainly from Spain, evaluated potential genetic predictors in association with NAR to NSAIDs (43) (44) (45) (46) (47) (48) (49) (50) . The first report by Quiralte et al. evaluated . This study did not show at the functional level that HLA-DRB1*11 alleles themselves were directly responsible for disease risk, although the strength of association suggested that HLA-DRB1*11 alleles could be an important determinant of this specific reaction to NSAIDs in susceptible individuals, unraveling MHC-encoded susceptibility in NSAID-induced anaphylactoid reactions (43) . The prevalence of HLA class I phenotypes and HLA-DRB1 genotype was assessed in 69 patients with aspirin and/ or NSAIDs hypersensitivity and 200 healthy subjects and did not identify any significant difference between patients and controls as regards to HLA-DRB1* genotypes (44) . This study was potentially underpowered for demonstrating a statistically significant difference for HLA-DRB1*11 alleles, but it showed that carriers of HLA-B44 phenotype had a higher risk of chronic idiopathic urticaria associated with aspirin and/or NAR to NSAIDs (44) .
The histamine-producing pathway genes Histamine is released and is responsible for some of the clinical symptoms, in NAR to aspirin and NSAID. A case-control study evaluated 7 SNPs using the TaqMan Ò assays on three histamine-producing pathway genes (HDC, HNMT, and DAO) in 442 unrelated Caucasian patients with hypersensitivity to NSAIDs and 414 healthy unrelated controls ethnically matched with patients and from the same geographic area in Malaga and Madrid (Spain) (45) . The nonsynonymous variant on the diamine oxidase gene (DAO rs10156191, p.Thr16Met) was moderately but significantly associated with cross-intolerance to NSAIDs (OR, 1.59; 95% CI, 1.27-2.00; P = 6 9 10 À5 for the minor allele) (45) . In contrast, HNMT was the only significant predictor of this pathway in NAR to aspirin (32, 33, 36) . Results from these studies suggest that mutations in genes encoding histaminemetabolizing enzymes may increase the risk, or modify the clinical presentation, of NAR, in which histamine plays an important role. The potential influence of variants of genes encoding histamine receptors (HRH gene family) on the expression of allergic diseases has been evaluated in a casecontrol study (47) . The authors analyzed copy number variations (CNVs) and common functional SNPs in genes HRH1, HRH2, and HRH4 in 442 unrelated patients with hypersensitivity to NSAIDs and in 414 healthy unrelated controls and found no influence of HRH genes variants on the primary risk for developing NSAIDs hypersensitivity (47).
The arachidonic acid pathway genes A large case-control study from the Spanish network RIR-AAF assessed 15 relevant genes encoding both enzymes and receptors from the arachidonic acid pathway in 486 patients with NIUA and 536 unrelated controls (46) . Among the 31 tested variants, seven were associated with NIUA risk in the initial study (46) . In the replication study, only three SNPs from the six initially significant variants were replicated Crohn's disease patients under infliximab In a case-control study, 563 adult patients with NIUA and 551 healthy control subjects without a history of NSAID hypersensitivity were enrolled (49) . This study investigated potential SNPs associated with isolated NECD from a predefined list of 217 SNPs in 48 genes involved in cyclooxygenase or lipoxygenase pathways or in inflammation (49) . The most significant association with NECD was found for the intronic variant rs6962291 on the TBXAS1 (thromboxane A synthase 1) gene (OR, 0.62; 95% CI, 0.49-0.77; P = 1.6 9 10 À5 ), which remained significant after multiple testing correction (49) . One intronic SNP on the ALOX5 (arachidonate 5-lipoxygenase) gene (rs4948672) was associated with an increased risk for isolated NECD (OR, 1.82; 95% CI, 1.25-2.65; P = 6.64 9 10
À3
) but did not reach multiple testing significance (49) . TBXAS1 catalyzes the conversion of prostaglandin H2 to thromboxane A2 which induces platelet aggregation and smooth muscle contraction (49) . The ALOX5 gene encodes a member of the lipoxygenase gene family and plays a dual role in the synthesis of leukotrienes from arachidonic acid. By comparison, the case-control studies performed on NAR to aspirin showed an association with three other genes of the arachidonic acid pathway, LTC4S, TBXA2R, and PTGER4, and only one, ALOX5, which was also associated with NAR to NSAIDs (33, 39, 41, 42) . This is consistent with the fact that aspirin and NSAIDs inhibit distinct enzymes of this pathway.
Other potential pathways A genomewide association study compared 232 NIUA cases (112 Spanish and 120 Han Chinese) with 225 unrelated controls (124 Spanish and 101 Han Chinese) using the Affymetrix Ò Genome-Wide Human SNP Array 6.0 (Affymetrix, CA, USA) (48) . Although no variant reached genomewide significance, possibly due to the limited study power, suggestive 
Pathways
LGALS3 Figure 4 Overview of pathogenetic pathways potentially involved in IgE-mediated beta-lactam allergy and nonspecific reactions to aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) (four pathogenic pathways were individualized based on genes retrieved from the systematic review: (i) cytokines signaling, (ii) HLA antigen processing, (iii) production and release of newly formed mediators, (iv) and production and release of preformed mediators).
associations were proposed for three clusters in the Spanish group (RIMS1, BICC1 and RAD51L 1) and one region in the Han Chinese population (ABI3BP). A recent genomewide association study highlighted the influence of the CEP68 (centrosomal protein of 68 KDa) gene on susceptibility to aspirin intolerance in asthmatics from Taiwan (62) . A Spanish case-control study assessed the role of this locus in NAR to NSAIDs by examining 53 common gene variants in a total of 635 patients with NIUA (n = 399), NERD (n = 110) or blended pattern (n = 126), compared to 425 controls. Seventeen variants on the CEP68 gene, including the nonsynonymous Gly74Ser variant (rs7572857) previously identified in asthmatic cases from Taiwan, were found to be associated with a reduced susceptibility for NIUA (lowest Pvalue = 1.13 9 10
À6
; OR, 0.33; 95% CI, 0.21-0.52) (50). Although the functions of the CEP68 protein are not fully understood, these results suggest that it may play an important role in NAR produced by NSAIDs.
Overview and limitations of reported data
The overall analysis of data reported in this systematic review highlights some limitations in the studies dedicated to genetic predictors of IgE-mediated AR and NAR. A first ascertainment is that most of the studies on genetic prediction of drug hypersensitivity have been performed using a gene-candidate design. Only one GWAS with replication was performed in IgE-mediated AR. This study showed that genetic susceptibility of HLA type 2 antigen presentation could play a central role in gene-environment interactions producing IR against penicillins. A second remark is that only four case-control studies were replicated, and three of them were related to AR against BLs. These three replicated studies evidenced the influence of three genes related to IgE production, atopy, and inflammation, namely IL4R, NOD2, and LGALS3 through potential interacting pathomechanisms that should deserve further interest (Figs 2 and 4) . Most of the case-control studies performed on NAR against aspirin and NSAIDs were not replicated, even if they were highly consistent in identifying genes involved in the arachidonic acid pathways as predictors (Figs 3 and 4) . Among these genes, ALOX5 has been reported as a predictor in two studies on NAR against aspirin and NSAIDs, respectively. In addition, these studies were performed in two contrasting world regions (29, 47) . The intriguing association of NAR to NSAIDs with atopy (47) suggests also a possible influence of genes related to atopy, which should deserve further attention.
In conclusion, this systematic review shows clear differences in the functional influence of the genes, which predict IgE-mediated AR against BLs and NAR against aspirin and NSAIDs, respectively. Those predicting AR to BLs are sustained by GWAS and replicated studies, which highlight the involvement of interacting mechanisms, HLA type 2 antigen presentation, IgE-class switching, and atopy. The strongest gene predictors of NAR against aspirin and NSAIDs are related to the synthesis of newly formed mediators of the arachidonic acid pathways. Other gene predictors suggest the possible involvement of mechanisms that regulate mediator release and inflammation. However, this present review also shows that data on this issue are still too sparse to draw more specific conclusions. The limited knowledge produced by the literature on the complex interactions between genetic variability and environmental exposure illustrates the need for performing GWAS and replications in contrasted populations, taking into account worldwide variations of allele frequencies, gene-gene interactions and contrasted situations of environmental exposure.
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